Lineage Cell Therapeutics (LCTX) vs Palisade Bio (PALI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Palisade Bio (PALI) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, losing 11.9% versus a loss of 45.2%. Over five years, LCTX leads with a -59.7% price change compared with -99.9% for PALI. Palisade Bio is the larger company by market cap ($249.2 million vs $236.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LCTX | PALI |
|---|---|---|
| Share price | $0.9362 | $1.43 |
| Market cap | $236.77M | $249.21M |
| 1-day change | -1.20% | -3.37% |
| YTD return | -43.26% | -37.02% |
| 1-year return | -45.23% | -11.90% |
| 5-year return | -59.68% | -99.93% |
| P/E ratio (TTM) | — | 2.38 |
| EPS (TTM) | $-0.19 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.09 | $2.86 |
| 52-week low | $0.88 | $1.32 |
| Distance from 52-week high | -55.21% | -50.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +487.48% | +614.69% |
| Average volume | 1.15M | 2.60M |
| Shares outstanding | 252.91M | 174.27M |
| Employees | 72 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PALI has outperformed LCTX by 33.3 percentage points over the past year.
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
LCTX vs PALI FAQ
Which is bigger, Lineage Cell Therapeutics or Palisade Bio?
Palisade Bio (PALI) is larger, with a market capitalization of $249.21M compared with $236.77M for Lineage Cell Therapeutics (LCTX).
Which stock has performed better over the past year, LCTX or PALI?
PALI returned -11.90% over the past 12 months, compared with -45.23% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are Lineage Cell Therapeutics and Palisade Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.